1993
Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis
Weiner H, Mackin G, Matsui M, Orav E, Khoury S, Dawson D, Hafler D. Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis. Science 1993, 259: 1321-1324. PMID: 7680493, DOI: 10.1126/science.7680493.Peer-Reviewed Original ResearchConceptsMultiple sclerosisOral tolerizationMyelin antigensAutoimmune diseasesDouble-blind pilot trialRelapsing-remitting multiple sclerosisDouble-blind studyCentral nervous systemMyelin basic proteinMajor exacerbationsDaily capsuleT cellsT lymphocytesPilot trialSide effectsNervous systemControl groupMyelin componentsBovine myelinDiseaseMyelinTolerizationSclerosisAntigenBasic protein
1987
Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
Dawson DM, Carter JL, Hafler DA, Weiner HL. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies. Nuova Rivista Di Neurologia 1987, 57: 88-91. PMID: 3039645.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisMonoclonal antibody therapyMultiple sclerosisAntibody therapyChronic progressive multiple sclerosisHigh-dose intravenous cyclophosphamideMultiple sclerosis patientsForm of treatmentLong-term controlIntravenous cyclophosphamideSclerosis patientsClinical resultsSerious toxicityImmune parametersPilot trialCyclophosphamideNervous systemSclerosisTerm controlsPatientsMonoclonal antibodiesACTHOnly small numbersTherapyAdverse effects